Patents by Inventor Christopher James ARP

Christopher James ARP has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF IGF-2 RECEPTOR AGONIST LIGANDS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM
    Publication number: 20240390405
    Abstract: Provided are methods for treatment of neurodevelopmental disorders, such as Angelman Syndrome and autism comprising administering to an individual a composition comprising an agonist ligand of IGF-2 receptor. The agonist ligand of IGF-2 receptor may be IGF-2, or mannose-6-phosphate or a derivative thereof. Compositions comprising mannose-6-phosphate derivatives are also disclosed.
    Type: Application
    Filed: August 6, 2024
    Publication date: November 28, 2024
    Inventors: Cristina Maria ALBERINI, Dirk TRAUNER, Christopher James ARP
  • Use of IGF-2 receptor agonist ligands for treatment of Angelman Syndrome and autism
    Patent number: 12083139
    Abstract: Provided are methods for treatment of neurodevelopmental disorders, such as Angelman Syndrome and autism comprising administering to an individual a composition comprising an agonist ligand of IGF-2 receptor. The agonist ligand of IGF-2 receptor may be IGF-2, or mannose-6-phosphate or a derivative thereof. Compositions comprising mannose-6-phosphate derivatives are also disclosed.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: September 10, 2024
    Assignee: New York University
    Inventors: Cristina Maria Alberini, Dirk Trauner, Christopher James Arp
  • USE OF MANNOSE 6 PHOSPHATE AND MODIFICATIONS THEREOF FOR MEMORY ENHANCEMENT AND REDUCING MEMORY IMPAIRMENT
    Publication number: 20210322451
    Abstract: Provided are compositions and methods for memory enhancement, including recovery of memory impairment. The compositions and methods relate to mannose-6-phosphate and derivatives of mannose-6-phosphate. The methods relate to administration of M6P or derivatives thereof to individuals in whom memory enhancement is desired.
    Type: Application
    Filed: August 12, 2019
    Publication date: October 21, 2021
    Inventors: Cristina Maria ALBERINI, Dirk TRAUNER, Christopher James ARP
  • USE OF IGF-2 RECEPTOR AGONIST LIGANDS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM
    Publication number: 20210315914
    Abstract: Provided are methods for treatment of neurodevelopmental disorders, such as Angelman Syndrome and autism comprising administering to an individual a composition comprising an agonist ligand of IGF-2 receptor. The agonist ligand of IGF-2 receptor may be IGF-2, or mannose-6-phosphate or a derivative thereof. Compositions comprising mannose-6-phosphate derivatives are also disclosed.
    Type: Application
    Filed: August 12, 2019
    Publication date: October 14, 2021
    Inventors: Cristina Maria ALBERINI, Dirk TRAUNER, Christopher James ARP